Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Accounts Payables: 2019-2024

Historic Accounts Payables for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $1.3 million.

  • C4 Therapeutics' Accounts Payables fell 11.37% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 11.37%. This contributed to the annual value of $1.3 million for FY2024, which is 8.16% down from last year.
  • Per C4 Therapeutics' latest filing, its Accounts Payables stood at $1.3 million for FY2024, which was down 8.16% from $1.4 million recorded in FY2023.
  • C4 Therapeutics' Accounts Payables' 5-year high stood at $5.7 million during FY2020, with a 5-year trough of $1.2 million in FY2022.
  • Its 3-year average for Accounts Payables is $1.3 million, with a median of $1.3 million in 2024.
  • Per our database at Business Quant, C4 Therapeutics' Accounts Payables plummeted by 73.99% in 2022 and then rose by 23.38% in 2023.
  • Over the past 5 years, C4 Therapeutics' Accounts Payables (Yearly) stood at $5.7 million in 2020, then declined by 20.71% to $4.5 million in 2021, then crashed by 73.99% to $1.2 million in 2022, then grew by 23.38% to $1.4 million in 2023, then dropped by 8.16% to $1.3 million in 2024.